A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

March 3, 2026

Study Completion Date

March 2, 2027

Conditions
Amyloidosis
Interventions
DRUG

Daratumumab

Daratumumab will be administered subcutaneously.

DRUG

Cyclophosphamide

Cyclophosphamide will be administered either orally or IV.

DRUG

Bortezomib

Bortezomib will be administered by SC injection or IV.

DRUG

Dexamethasone

Dexamethasone will be administered orally or IV.

Trial Locations (46)

10021

Memorial Sloan Kettering, New York

11528

Alexandra General Hospital of Athens, Athens

12203

Charite Campus Benjamin Franklin, Berlin

15224

West Penn Hospital, Pittsburgh

23219

VCU Medical Center, Richmond

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

27157

Wake Forest University - Baptist Medical Center, Winston-Salem

28027

Clinica Univ. de Navarra, Madrid

28204

Levine Cancer Institute, Charlotte

30322

Winship Cancer Institute Emory University, Atlanta

31008

Clinica Univ. de Navarra, Pamplona

31400

CHU Rangueil, Toulouse

33612

Moffitt Cancer Center, Tampa

37007

Hosp Clinico Univ de Salamanca, Salamanca

43214

Ohio Health Research Institute, Columbus

44106

University Hospital of Cleveland, Cleveland

45122

Universitatsklinikum Essen, Essen

48201

Barbara Ann Karmanos Cancer Institute, Detroit

69120

Universitaetsklinikum Heidelberg Medizinische Klinik V, Heidelberg

69495

Centre hospitalier Lyon-Sud, Pierre-Bénite

75390

UT Southwestern Medical Center, Dallas

80131

Università Degli Studi Di Napoli Federico Ii, Napoli

86000

CHU De Poitiers, Poitiers

87042

CHU de Limoges, Limoges

90805

University of Washington, Seattle

91010

City of Hope, Duarte

100034

Peking University First Hospital, Beijing

100044

Peking University People s Hospital, Beijing

200025

Ruijin Hospital Shanghai Jiao Tong University, Shanghai

310020

First affiliated Hospital of Zhejiang University, Hangzhou

610041

West China Hospital Si Chuan University, Chengdu

06510

Smilow Cancer Hospital/Yale Cancer Center, New Haven

02111

Tufts Medical Center, Boston

02118

Boston University Medical Center, Boston

T2N 4N2

Tom Baker Cancer Center, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

M5G 2M9

University Health Network UHN Princess Margaret Cancer Centre, Toronto

00161

DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA - UNIVERSITà ''LA SAPIENZA'', Roma

9713 GZ

University Medical Center Groningen, Groningen

6229 HX

Hospital Maastricht University Medical Center, Maastricht

3584 CX

UMC Utrecht, Utrecht

08916

Hosp. Univ. Germans Trias I Pujol, Badalona

08035

Hosp Univ Vall D Hebron, Barcelona

08036

Hosp Clinic de Barcelona, Barcelona

LE1 5WW

Leicester Royal Infirmary - Haematology, Leicester

NW1 2PG

University College Hospital, London

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY